Therapeutics Company Reveals Pre-clinical Data For Integrase Technology
The MINT platform, derived from Sangamo's extensive experience in protein-DNA interactions through its zinc finger technology.
Sangamo Therapeutics recently presented critical pre-clinical data on its innovative next-generation integrase technology, the Modular Integrase (MINT) platform, highlighting a significant advancement in the field of genome editing. The announcement came as part of their participation at the 27th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, emphasizing the potential of this technology to revolutionize treatments for patients with unique mutations within the same gene. $Sangamo Therapeutics(SGMO.US$
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
